260 related articles for article (PubMed ID: 36647006)
21. Erenumab for episodic migraine.
Datta A; Gupta S; Maryala S; Aggarwal V; Chopra P; Jain S
Pain Manag; 2022 Jul; 12(5):587-594. PubMed ID: 35313740
[TBL] [Abstract][Full Text] [Related]
22. Real-Life Response to Erenumab in a Therapy-Resistant Case Series of Migraine Patients From the Province of Québec, Eastern Canada.
Eghtesadi M; Leroux E; Pagé G
Clin Drug Investig; 2021 Aug; 41(8):733-739. PubMed ID: 34287786
[TBL] [Abstract][Full Text] [Related]
23. Twelve-month safety, tolerability and susceptibility to adverse events of prophylactic migraine therapy with erenumab: a retrospective real-world study.
Schenk H; Holle D; Nsaka M; Kleinschnitz C; Glas M; Scheffler A
J Headache Pain; 2022 May; 23(1):55. PubMed ID: 35538414
[TBL] [Abstract][Full Text] [Related]
24. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
[TBL] [Abstract][Full Text] [Related]
25. Erenumab and galcanezumab in chronic migraine prevention: effects after treatment termination.
Raffaelli B; Mussetto V; Israel H; Neeb L; Reuter U
J Headache Pain; 2019 Jun; 20(1):66. PubMed ID: 31159727
[TBL] [Abstract][Full Text] [Related]
26. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis.
Tepper SJ; Lipton RB; Silberstein SD; Kudrow D; Ashina M; Reuter U; Dodick DW; Wang A; Cheng S; Klatt J; Mikol DD
Headache; 2023 Jun; 63(6):730-742. PubMed ID: 37313616
[TBL] [Abstract][Full Text] [Related]
27. Real-world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real-world study.
Gladstone J; Chhibber S; Minhas J; Neish CS; Power GS; Lan Z; Rochdi D; Lanthier-Martel J; Bastien N
Headache; 2022 Jan; 62(1):78-88. PubMed ID: 34807454
[TBL] [Abstract][Full Text] [Related]
28. Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.
Gantenbein AR; Agosti R; Kamm CP; Landmann G; Meier N; Merki-Feld GS; Petersen JA; Pohl H; Ryvlin P; Schankin CJ; Viceic D; Zecca C; Schäfer E; Meyer I; Arzt ME
J Headache Pain; 2022 Nov; 23(1):142. PubMed ID: 36401172
[TBL] [Abstract][Full Text] [Related]
29. Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment - real world outcomes.
Talbot J; Stuckey R; Crawford L; Weatherby S; Mullin S
J Headache Pain; 2021 Jan; 22(1):5. PubMed ID: 33421995
[TBL] [Abstract][Full Text] [Related]
30. Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study.
Cullum CK; Do TP; Ashina M; Bendtsen L; Hugger SS; Iljazi A; Gusatovic J; Snellman J; Lopez-Lopez C; Ashina H; Amin FM
J Headache Pain; 2022 Jun; 23(1):61. PubMed ID: 35655137
[TBL] [Abstract][Full Text] [Related]
31. Effectiveness and safety of erenumab and galcanezumab in the prevention of chronic and episodic migraine: A retrospective cohort study.
Viudez-Martínez A; Pascual-Carrasco A; Beltrán-Blasco I; Hernandez-Lorido R; F Ruiz de Apodaca R
J Clin Pharm Ther; 2022 Jun; 47(6):814-823. PubMed ID: 35212025
[TBL] [Abstract][Full Text] [Related]
32. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
33. Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany.
Straube A; Stude P; Gaul C; Schuh K; Koch M
J Headache Pain; 2021 Nov; 22(1):133. PubMed ID: 34742252
[TBL] [Abstract][Full Text] [Related]
34. Erenumab Efficacy on Comorbid Cluster Headache in Patients With Migraine: A Real-World Case Series.
Silvestro M; Tessitore A; Scotto di Clemente F; Tedeschi G; Russo A
Headache; 2020 Jun; 60(6):1187-1195. PubMed ID: 32359106
[TBL] [Abstract][Full Text] [Related]
35. Timing and durability of response to erenumab in patients with episodic migraine.
McAllister PJ; Turner I; Reuter U; Wang A; Scanlon J; Klatt J; Chou DE; Paiva da Silva Lima G
Headache; 2021 Nov; 61(10):1553-1561. PubMed ID: 34841526
[TBL] [Abstract][Full Text] [Related]
36. Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study.
Ornello R; Baraldi C; Guerzoni S; Lambru G; Andreou AP; Raffaelli B; Gendolla A; Barbanti P; Aurilia C; Egeo G; Cevoli S; Favoni V; Vernieri F; Altamura C; Russo A; Silvestro M; Valle ED; Mancioli A; Ranieri A; Alfieri G; Latysheva N; Filatova E; Talbot J; Cheng S; Holle D; Scheffler A; Nežádal T; Čtrnáctá D; Šípková J; Matoušová Z; Casalena A; Maddestra M; Viola S; Affaitati G; Giamberardino MA; Pistoia F; Reuter U; Sacco S
J Headache Pain; 2022 Mar; 23(1):38. PubMed ID: 35305579
[TBL] [Abstract][Full Text] [Related]
37. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
38. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score.
Iannone LF; Fattori D; Benemei S; Chiarugi A; Geppetti P; De Cesaris F
CNS Drugs; 2022 Feb; 36(2):191-202. PubMed ID: 35146696
[TBL] [Abstract][Full Text] [Related]
40. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
